As the main goal of this study is to utilize the above engineered exosomes to deliver CRISPR/Cas9 to treat HCC, next we designed two different sgRNA sequences against two different sites of human locus IQGAP1 and named sgIQ 1.1 and sgIQ 1.2, respectively (Fig. S2). This evidence concerns the gene IQGAP1 and hepatocellular carcinoma.